Vall d'Hebron
Search

Home > Research Programs > Head, Neck and Gynecological Tumors Group

More groups

Head, Neck and Gynecological Tumors Group

Strategic Goals

  1. Reference Center in Patient Care and Clinical Research
  2. Highly specialized in treatment
    a. Training in Gynecological Oncology
    b. Fellowships
  3. International projection
  4. Potentiate scientific activity
    a. Publications in impact journals
    b. Communications in international conferences

Current objectives

  • Our team aims to consolidate itself as a reference center by creating high-level multidisciplinary teams. To this end, we will encourage training of specialists involved in gynecological and head and neck tumors by means of a Fellowship in International Reference Hospitals.
  • We will create a regional network of hospitals to facilitate patient access to novel treatments in clinical trials that are currently limited to reference centers.
  • We aim to form part of the management structures of the cooperative groups of greatest international relevance (ENGOT, GCIG) and strengthen relations with highly specialized centers in our areas of interest (NCIC, Peter McCallum CC, Irvine MC, HSK Wiesbaden).
  • We will develop our own database for each disease, which allows for exhaustive reviews of practical interest and of publishing potential.
  • We will increase communications in international forums and publications in impact journals.

Team

Josep Maria del Campo

Principal Investigator

Medical Oncologists

  • Ana Oaknin MD
  • Isabela Diaz de Corcuera MD

Publications

  • Cedrés S, Prat A, Martínez P, Pallisa E, Sala G, Andreu J, del Campo JM, Quispe I, Baselga J, Felip E. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer 2009 Nov; 66(2): 257-61
  • Prat A, Parera M, Adamo B, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, Baselga J, del Campo JM. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann. Oncol. 2009 Feb; 20(2): 294-7
  • del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wojtukiewicz MZ, Poveda A, Boman K, Westermann AM, Lebedinsky C. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann. Oncol. 2009 Nov; 20(11): 1794-802
  • Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, Kaye S. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur. J. Cancer 2009 Sep; 45(13): 2324-32